| Name | Title | Contact Details |
|---|
We are T-Bird Pharma Inc., a public company listed on the TSX-V. We are the parent company to Thunderbird Biomedical Inc. Thunderbird is a licensed medical marijuana producer operating within the parameters of Health Canada`s MMPR. Thunderbird obtained a medical marijuana license to undertake the production of medical marijuana in February 2014, being the fifth company in Canada to obtain such a license. T-Bird is the publicly traded parent company of Thunderbird.
Biorasi is an award-winning full service, global Clinical Research Optimized (CRO). From project design to execution success, optimization is engrained in ProAct+. An integrated platform of high performance systems, tools, and processes. By developing and implementing groundbreaking methods of optimizing clinical research, we contribute to enhancement of health and well-being for people around the world. Powered by ProAct+, Biorasi`s full service project teams have developed numerous drugs, biologics and devices that received FDA and multi-venue approvals. Biorasi is headquartered in Miami, FL and has regional operations around the world.
Headquartered in Walnut Creek, CA, BASS Medical Group is the Greater Bay Area’s leading healthcare specialist provider. With over 300 providers, 200 locations, & 42 specialties, BASS provides state-of-the-art care in a family setting. Known for its sma...
AlgoRx Pharmaceuticals is a Wilton, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, the Company’s gene control platform has broad potential to achieve profound and durable benefit across a range of diseases. Syros is focused on cancer and immune-mediated diseases and is advancing a growing pipeline, including its lead drug candidates SY-1425, a selective RARα agonist for genomically defined subsets of patients identified by its platform, for a range of cancers including acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor for a range of blood cancers and solid tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.